Other analysts have also issued reports about the company. HC Wainwright reiterated a buy rating and set a $3.50 price objective on shares of Trevena in a research note on Tuesday, November 5th. Zacks Investment Research downgraded Trevena from a hold rating to a sell rating in a research note on Saturday, November 23rd.
Trevena stock opened at $0.68 on Tuesday. The firm has a 50 day simple moving average of $0.82 and a 200 day simple moving average of $0.95. The company has a current ratio of 3.31, a quick ratio of 3.31 and a debt-to-equity ratio of 0.23. Trevena has a 1-year low of $0.38 and a 1-year high of $2.00. The firm has a market capitalization of $62.73 million, a price-to-earnings ratio of -1.61 and a beta of 2.54.
Large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Trevena by 11.5% during the 2nd quarter. Vanguard Group Inc. now owns 3,915,315 shares of the biopharmaceutical company’s stock worth $4,032,000 after acquiring an additional 403,060 shares during the period. BlackRock Inc. boosted its holdings in Trevena by 1.9% in the 2nd quarter. BlackRock Inc. now owns 2,647,830 shares of the biopharmaceutical company’s stock valued at $2,727,000 after purchasing an additional 49,900 shares during the period. Renaissance Technologies LLC grew its position in shares of Trevena by 50.2% during the 2nd quarter. Renaissance Technologies LLC now owns 1,928,850 shares of the biopharmaceutical company’s stock valued at $1,987,000 after purchasing an additional 644,812 shares in the last quarter. Morgan Stanley grew its position in shares of Trevena by 2,651.1% during the 2nd quarter. Morgan Stanley now owns 530,436 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 511,155 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in shares of Trevena during the 2nd quarter valued at $264,000. 20.47% of the stock is owned by institutional investors.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.
Further Reading: Balanced Fund
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.